ArticleChemMedChem2026
Probing 5-Nitroimidazole-Triazole Hybrids as Potential Anti-Kinetoplastid Agents: Synthesis and In Vitro Efficacy.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Neglected tropical diseases caused by kinetoplastid parasites, including leishmaniasis, human African trypanosomiasis and Chagas disease, remain severely underserved by current chemotherapies, which are limited by toxicity, resistance and poor efficacy. Nitroheterocycles continue to be clinically relevant due to their redox activation within parasites, and the 1,2,3-triazole linker offers a modular approach by enabling systematic variation of substituents, thereby allowing controlled modulation of physicochemical and biological properties. Accordingly, this study investigated a new library of 5-nitroimidazole-1,2,3-triazole hybrids and evaluated substituent-dependent effects on their antiparasitic activity. A series of 5-nitroimidazole-1,2,3-triazole hybrids was synthesised via copper(I)-catalysed azide-alkyne cycloaddition and evaluated in vitro for their antileishmanial and antitrypanosomal activity, alongside cytotoxicity profiling. Most compounds exhibited low toxicity against mammalian cell lines. No antileishmanial hit was uncovered. In the trypanosome panel, 3j demonstrated selective micromolar inhibition against Trypanosoma congolense (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.